Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Sales reflect continued strong growth in oncology and vaccines
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Fluid bed processes: drying, granulating, and coating in just one product container
Subscribe To Our Newsletter & Stay Updated
